After the operation, each person receives one of the two medicines through a vein. The treatment is given in the recovery period after surgery, and the medical team follows the person during the hospital stay to watch how the heart, lungs, kidneys, and other organs recover. The study is open label, which means the treatment is known to the medical team and the person receiving it.

The main outcome is the change in mean pulmonary arterial pressure, which is the pressure in the main blood vessel carrying blood from the heart to the lungs. Other hospital problems may also be watched, such as kidney failure, atrial fibrillation or atrial flutter (irregular heart rhythms), stroke, pneumonia, bleeding from the airways, and death. The study is planned to run over several years while enough people are enrolled and followed after surgery.

Participants in the study will receive either the IKT-001 film-coated tablet or a placebo. The study is designed in two parts to observe how the medication affects different aspects of the condition over a period of time. During the study, changes in pulmonary vascular resistance, which is the resistance to blood flow through the lung vessels, and the six-minute walk distance, which is a test measuring how far a person can walk in six minutes to assess physical capacity, will be monitored.

REGN13335 is a monoclonal antibody, which is a type of laboratory-made protein designed to target specific parts of the body. In this case, the drug targets Platelet-Derived Growth Factor Subunit B, also known as PDGF-B, a substance that can contribute to the thickening of the blood vessel walls in the lungs. During the study, participants will receive either REGN13335 or a placebo through an injection or infusion.

The study will monitor several health factors, such as pulmonary vascular resistance, which is the amount of force the blood must overcome to flow through the lung vessels. Other areas of focus include cardiac output, which is the amount of blood the heart pumps each minute, and the distance a person can walk in six minutes. The course of the study involves regular assessments to track how the body responds to the treatment and to monitor for any side effects.

The purpose of the study is to evaluate how ROC-101 affects the resistance to blood flow in the lung blood vessels and to determine if the medication is safe and well tolerated when given by mouth. The study will also look at other measures of how well the heart and lungs are working. During the study, participants will continue taking their usual medications for their lung condition while also taking ROC-101 for up to 24 weeks. Some participants may be able to continue in an extension period beyond 24 weeks. The study will measure changes in lung blood vessel resistance using a procedure called right heart catheterization, which involves inserting a thin tube into the heart through a blood vessel to measure pressures and blood flow.

Throughout the study, participants will have regular visits where doctors will check their safety through physical examinations, blood tests, heart tracings, and monitoring for any side effects. The study will also measure how far participants can walk in six minutes, check levels of a substance in the blood called NT-proBNP that indicates heart stress, and assess symptom severity. Additional measurements will include various heart and lung pressures, oxygen levels in the blood, and how much blood the heart pumps with each beat. Participants will need to use effective birth control methods during the study and for a period after stopping the medication.

The purpose of the study is to evaluate the long-term safety and how well the body tolerates repeated doses of PF-07868489 in people with this lung blood pressure condition. This is an extension study, which means it is designed for people who have already participated in an earlier clinical trial with the same medication and completed at least 20 weeks of treatment in that previous study. The study will continue for up to 104 weeks, which is about two years.

During the study, participants will receive regular injections of the medication under the skin and will attend scheduled visits where various health checks will be performed. These checks will include monitoring for any unwanted effects or serious health problems, measuring vital signs such as blood pressure and heart rate, taking blood samples for laboratory tests, and performing heart recordings using an electrocardiogram. The study will also measure certain substances in the blood and check whether the body develops any immune response to the medication over time.

This study is designed for people who have already completed a previous study called MK-7962-004. People who join this study will continue to receive sotatercept for up to 36 months while being closely monitored. During the study, doctors will check for any unwanted effects or side effects that might occur, and they will measure various health indicators through blood tests and other examinations. These tests will look at things like red blood cells, white blood cells, liver function, kidney function, and other important markers in the blood.

Throughout the study, doctors will also measure how well the treatment is working by checking several things, including how far people can walk in six minutes, levels of a substance in the blood that indicates heart stress, blood pressure in the lung arteries, and whether people’s overall functional status improves or stays stable. The study will also check if people develop any immune response to the medication by testing for antibodies. Regular monitoring will include checking body weight, blood pressure, and heart electrical activity to ensure safety during the treatment period.

The purpose of the study is to see whether imaging with [68Ga]Ga-FAPI can help doctors see changes in the blood vessels of the lungs in people with pulmonary arterial hypertension without needing invasive procedures. The study will look at whether this imaging method can show these changes and whether the changes can be seen after treatment with sotatercept. The study will also look at how the imaging results relate to other measurements of how well the heart and lungs are working, such as exercise ability and blood test results.

People in the study will have imaging scans at the beginning and then again after receiving treatment with sotatercept. The imaging will include scans using both [68Ga]Ga-FAPI and [68Ga]Ga-MAA to look at different aspects of the blood vessels and blood flow in the lungs. The study will also measure how well the right side of the heart is working and compare the imaging results with other tests that are commonly used to check pulmonary arterial hypertension, including heart function tests, walking tests, and blood tests. The entire study is expected to last until March 2027.

The study will test calcifediol given orally once every ten days for the first 12 weeks, followed by doses every two weeks for another 12 weeks. Two additional supplements will also be used in the study: triglycerides medium chain and alpha-tocopherol (a form of vitamin E). The total treatment period will last 24 weeks.

The main goal is to determine if this vitamin D supplementation leads to improvements in various aspects of the disease, including walking ability, heart function measurements, and overall risk level of the disease. The study will monitor how well patients tolerate the treatment and track any changes in their condition throughout the study period.

The research aims to understand if LTP001 is effective in treating people with PAH when added to their standard treatments. The study will be conducted in two parts – first testing the medication in healthy volunteers to ensure its safety, followed by testing in people who have PAH. During the study, some participants will receive LTP001 while others will receive placebo, along with their regular PAH medications.

The study will monitor how well the treatment works over 24 weeks, followed by a longer period of up to 18 months. Participants will have regular check-ups to assess their ability to walk and their overall health status. The study will look at how the treatment affects blood pressure in the lungs and how far participants can walk in a set time period.

The research will examine which treatment strategy is more effective at controlling the disease after 6 months in newly diagnosed patients who also have heart and blood vessel-related health conditions. During the study, participants will be divided into two groups. One group will receive both ambrisentan and tadalafil, while the other group will receive tadalafil and a placebo. The treatment period will last approximately 175 days.

Throughout the study, various aspects of the participants’ health will be monitored, including their ability to exercise, heart function, and overall well-being. The medications being tested are already approved for medical use, but they will be studied in a specific combination to determine if this approach provides better results for patients with additional cardiovascular health conditions.

The purpose of this research is to evaluate how the heart’s right chamber functions and whether it improves after treatment with Empagliflozin in people with PAH. During the study, participants will receive either Empagliflozin capsules or placebo capsules to take by mouth. The treatment period will last for 4 weeks, with a daily dose of 10 milligrams of Empagliflozin for those in the treatment group.

Throughout the study, various tests will be performed to monitor heart function, including heart imaging tests and measurements of blood flow in the lungs. The study will also track how well participants can exercise, their breathing capacity, and how they feel during daily activities. Participants will continue their regular PAH medications while participating in this study.

The purpose of the study is to understand how macitentan is processed in the body, as well as to evaluate its safety and effectiveness in treating children with pulmonary arterial hypertension. The study will involve children taking macitentan or receiving standard care, and their progress will be monitored over time. The study will also include a period where all participants will receive macitentan to gather more information about its long-term effects.

Participants will be observed for changes in their condition, including how well they can perform physical activities and their overall quality of life. The study will also track any hospitalizations related to pulmonary arterial hypertension and monitor the participants’ health through regular check-ups. The trial is expected to continue until late 2025, providing valuable insights into the treatment of this condition in children.

The purpose of the study is to evaluate the long-term safety and tolerability of sotatercept. Participants will receive sotatercept through injections under the skin. The study will monitor participants over a period to observe any side effects or adverse events that may occur. The study aims to ensure that sotatercept can be safely used by people with PAH as part of their standard care.

Participants in this study will have completed a previous study involving sotatercept and will not have started treatment with commercially available sotatercept. The study will track the number of participants who experience adverse events and those who discontinue the study due to these events. This information will help determine the safety of sotatercept for long-term use in managing PAH.

The purpose of this study is to evaluate how Sotatercept affects the function of the right side of the heart in patients with PAH. The study will observe changes in how the heart works and how it interacts with the blood vessels in the lungs. Participants will receive Sotatercept over a period of 24 weeks, and various heart functions will be monitored to assess the treatment’s impact.

This study is designed to provide insights into how Sotatercept can help manage PAH by improving heart function. The trial is open-label, meaning both the researchers and participants know what treatment is being administered. The information gathered from this study aims to enhance understanding of PAH treatment and potentially improve outcomes for those affected by this condition.

The purpose of the study is to learn how the medicine PF-07868489 is tolerated and how it acts in both healthy adults and those with PAH. Participants will receive either the study medicine or a placebo. The study will monitor how the medicine affects the body, including changes in blood pressure and other health indicators. The trial will also look at how the medicine influences a specific blood marker related to heart function, known as NTproBNP, over a period of time.

Participants in the study will receive repeat doses of the study medicine or placebo and will be monitored for any changes in their health. The study will track various health parameters, such as heart rate and blood pressure, to ensure the safety and effectiveness of the treatment. The trial aims to provide valuable information on the potential benefits of PF-07868489 for individuals with Pulmonary Arterial Hypertension.

The purpose of the study is to understand how sotatercept is absorbed and processed in the body when given in different ways based on a person’s weight. Participants will receive sotatercept through a subcutaneous injection, which means it is injected under the skin. The study will last for 24 weeks, during which participants will receive multiple doses of the medication. Researchers will monitor the levels of sotatercept in the blood and check for any side effects or adverse events that may occur during the treatment period.

By participating in this study, researchers aim to gather important information about the safety and effectiveness of sotatercept for treating PAH. This information could help improve treatment options for people living with this condition. The study will not only look at how the drug is processed in the body but also ensure that it is safe and well-tolerated by participants over the course of the treatment.

Participants in the study will be randomly assigned to receive either the 10 mg or 75 mg dose of Macitentan. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. After the initial phase, all participants will have the opportunity to receive the 75 mg dose of Macitentan in an open-label period, meaning everyone will know they are receiving the active medication.

The study will last for a period of up to 72 weeks, during which participants will be monitored for any changes in their condition and any side effects they may experience. The goal is to determine if the higher dose of Macitentan can better manage the symptoms of PAH and improve the quality of life for those affected by this condition. Participants will be required to visit the study site regularly for check-ups and assessments throughout the study period.

Participants in the study will receive either sotatercept or a placebo, in addition to their existing PAH therapy. The study will monitor the time to the first event of all-cause death, lung transplantation, or PAH worsening-related hospitalization lasting 24 hours or more. The study aims to understand how sotatercept affects these outcomes in people with severe PAH. The treatment period is expected to last up to 40 weeks, during which participants will have regular check-ups and assessments to track their health and response to the treatment.

This study is designed to provide valuable information on the potential benefits of sotatercept for individuals with severe PAH, helping to determine if it can improve survival and reduce the need for lung transplantation or hospitalization due to worsening PAH. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The purpose of this study is to evaluate the safety and tolerability of long-term use of Treprostinil Palmitil Inhalation Powder in people with PAH. Participants in the study will use the inhalation powder over a period of time, and their health will be monitored to see how well they tolerate the treatment and to check for any side effects. Some participants may receive a placebo, which looks like the treatment but does not contain the active medication. The study will help researchers understand how safe and effective the treatment is for managing PAH over an extended period.

Throughout the study, participants will have regular check-ups to monitor their condition and the effects of the treatment. These check-ups will include assessments of their physical health and any changes in their symptoms. The study aims to provide valuable information on the long-term use of Treprostinil Palmitil Inhalation Powder, which could lead to improved treatment options for people living with Pulmonary Arterial Hypertension.

Participants in the study will receive either sotatercept or a placebo, in addition to their current PAH treatment. The study will monitor the participants over a period to assess the impact of the treatment on their condition. The trial aims to understand how sotatercept affects the progression of PAH and whether it can improve the health outcomes for those affected by this disease.

The study will involve regular check-ups and assessments to track the participants’ health and response to the treatment. This includes monitoring exercise performance and other health indicators related to PAH. The trial is designed to provide valuable information on the potential benefits of sotatercept for individuals with PAH, contributing to the development of more effective treatment options for this challenging condition.

The purpose of this study is to evaluate the long-term safety and tolerability of sotatercept in adults with PAH. Participants in the study will receive sotatercept through an injection under the skin. The study will follow participants over a period to monitor their health and any side effects they may experience. This is an open-label study, meaning that both the researchers and participants know what treatment is being administered.

Throughout the study, participants will have regular check-ups to assess their health, including tests like blood work and heart monitoring. The study aims to gather information on how well sotatercept works in the long term and its impact on the participants’ overall health and quality of life. This information will help determine the potential benefits and risks of using sotatercept as a treatment for PAH.

Participants in the study will use the inhaler to take the medication regularly. The study will monitor the occurrence of any side effects and assess changes in the participants’ ability to walk a certain distance in six minutes, which is a common way to measure physical endurance in people with PAH. This study is an open-label extension, meaning that all participants will receive the active medication rather than a placebo.

The study aims to provide valuable information about the long-term use of seralutinib for treating Pulmonary Arterial Hypertension. By participating, individuals who have completed a previous study with this medication can continue to receive treatment while contributing to the understanding of its safety and benefits over time.

The purpose of the study is to evaluate the safety and effectiveness of KER-012 in improving the condition of patients with PAH. Participants will receive either KER-012 or a placebo, and the study will monitor changes in their health over time. The trial will last for a period of up to 96 weeks, during which participants will have regular check-ups to assess their response to the treatment. The main focus will be on how KER-012 affects the blood flow in the lungs and the ability of participants to perform physical activities, such as walking.

Throughout the study, researchers will also keep track of any side effects or adverse reactions that participants may experience. This will help determine the overall safety of KER-012. The study aims to provide valuable information on whether KER-012 can be a beneficial addition to existing PAH treatments, potentially improving the quality of life for those living with this challenging condition.

The purpose of the study is to evaluate the safety and tolerability of treprostinil sodium in children with Pulmonary Arterial Hypertension. Participants in the study will receive the treatment either through subcutaneous (under the skin) or intravenous (into a vein) methods. The study will monitor the frequency and seriousness of any adverse events or reactions to the drug over a period of time. Additionally, changes in the quality of life and other health parameters will be assessed to understand the impact of the treatment.

The study is open-label, meaning that both the researchers and participants will know which treatment is being administered. It is a single-arm trial, which means all participants will receive the same treatment without a comparison group. The trial is expected to run for several years, allowing researchers to gather comprehensive data on the effects of treprostinil sodium in treating Pulmonary Arterial Hypertension in children.

The purpose of this study is to find the best dose of AV-101 for treating PAH and to evaluate its safety and effectiveness. Participants in the study will be randomly assigned to receive either AV-101 or a placebo. The study will last for 24 weeks, during which time participants will take the medication and have regular check-ups to monitor their health and the effects of the treatment. The study is divided into two parts: Phase 2b, which focuses on finding the optimal dose, and Phase 3, which confirms the effectiveness of the treatment.

Throughout the study, participants will undergo various assessments, including a test called right heart catheterization, which helps measure changes in the pressure in the lungs. Another important measure is the 6-minute walk distance (6MWD), which evaluates how far a person can walk in six minutes. These assessments will help determine how well the treatment is working and ensure it is safe for patients with PAH. The study aims to improve the quality of life for those affected by this condition by finding a more effective treatment option.

The purpose of this study is to ensure that AV-101 is safe for long-term use in individuals who have already completed a previous study involving this treatment. Participants will continue to use AV-101 and will be monitored for any side effects or changes in their condition. The study will also look at how AV-101 affects certain health measures, such as the distance a person can walk in six minutes, levels of a heart-related protein called NT-proBNP, and heart function as seen in an ultrasound test called a cardiac echo.

Throughout the study, participants will receive regular check-ups to assess their health and the effects of the treatment. The study aims to provide valuable information on the safety and potential benefits of AV-101 for people living with PAH. This research is important for understanding how this treatment can help manage the condition over a longer period.

The purpose of the study is to evaluate how safe and tolerable seralutinib is for people with PAH over a long period. Participants in the study will continue using the medication and will be monitored for any side effects or changes in their condition. The study will also look at how the treatment affects the distance participants can walk in six minutes, which is a common way to measure physical ability in people with PAH.

Participants will be involved in the study for up to 52 weeks, during which they will have regular check-ups and tests to ensure their safety and to gather information about the treatment’s effects. The study will help researchers understand more about the long-term use of seralutinib and its potential benefits for people living with Pulmonary Arterial Hypertension.

Participants in the study will be randomly assigned to receive either TPIP or a placebo. The study will last for 16 weeks, during which participants will use an inhaler device to take the medication or placebo. The inhaler is a dry powder inhaler, which means it delivers the medication in the form of a fine powder that is inhaled into the lungs. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. These check-ups will include tests like the six-minute walk test, which measures how far a person can walk in six minutes, and other assessments to track changes in their condition.

The study aims to provide valuable information about the potential benefits of TPIP for people with PAH. By comparing the effects of TPIP with a placebo, researchers hope to understand how well the treatment works and its safety profile. This information could help in developing better treatment options for those living with PAH. Participants will be closely monitored to ensure their safety and well-being throughout the study period.

Participants in the study will be randomly assigned to receive either the triple therapy or the double oral therapy. The triple therapy consists of an oral endothelin receptor antagonist (ERA), an oral phosphodiesterase-5 inhibitor (PDE-5i), and parenteral treprostinil. The double oral therapy includes only the oral ERA and PDE-5i. The study will monitor participants over a period of time to assess their risk status and any changes in their condition. This will help determine how well the treatments work and their safety.

The study will last for a maximum of 720 days, during which participants will undergo various assessments to track their progress. These assessments will include checking heart and lung function and evaluating any side effects or adverse reactions to the treatments. The goal is to see if the triple therapy can help achieve a low-risk status in patients more effectively than the double oral therapy. Participants will be closely monitored to ensure their safety throughout the study.

The purpose of the study is to assess how seralutinib affects exercise capacity after 24 weeks of treatment when used alongside existing PAH medications. Participants will be randomly assigned to receive either seralutinib or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for a total of 48 weeks, during which participants will continue their regular PAH treatment while adding the study medication or placebo.

Throughout the study, participants will undergo various assessments to monitor their health and the effects of the treatment. These assessments will include measuring the distance they can walk in six minutes, which helps evaluate their exercise capacity. The study aims to provide valuable information on whether seralutinib can improve the quality of life for individuals with PAH by enhancing their ability to exercise and perform daily activities.

The purpose of the study is to evaluate the safety and tolerability of sotatercept over a period of 24 weeks. Participants will receive sotatercept through an injection under the skin, and the study will monitor how the body processes the medication. The trial will also observe any side effects that may occur during the treatment period. Throughout the study, various health parameters will be checked, including blood tests and blood pressure measurements, to ensure the well-being of the participants.

This study aims to provide valuable information on how sotatercept works in children with PAH and whether it can be a safe addition to their current treatment. The trial will help researchers understand the potential benefits and risks of using sotatercept in this young population, contributing to the development of better treatment options for PAH in children.

Participants in the study will receive either Selexipag or a placebo, in addition to their usual treatment for PAH. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The study will also include an open-label extension period, where all participants may receive Selexipag after the initial phase. The treatment will be given in the form of film-coated tablets, taken orally.

The study will last for a period of up to 96 weeks, during which the participants’ health and response to the treatment will be closely monitored. The main goal is to determine how long it takes for the disease to progress in participants taking Selexipag compared to those taking a placebo. This information will help researchers understand the effectiveness and safety of Selexipag as an add-on treatment for children with PAH.

The purpose of the study is to assess how well MK-5475 works in reducing the resistance in the blood vessels of the lungs and improving the distance participants can walk in six minutes. The study is divided into two phases. In the first phase, the focus is on the change in pulmonary vascular resistance, which is a measure of the pressure in the lung arteries, after 12 weeks of treatment. In the second phase, the study looks at the change in the six-minute walk distance after 12 weeks and again after 24 weeks. Participants will be randomly assigned to receive either MK-5475 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will be monitored for any side effects or adverse events. The study aims to provide valuable information on the potential benefits and risks of using MK-5475 for treating PAH. This research could lead to new treatment options for individuals living with this challenging condition.

Participants in the study will be randomly assigned to receive either AZD3427 or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effects of the treatment.

The main goal is to see if AZD3427 can improve the condition of the blood vessels in the lungs, which is measured by a test called right heart catheterization. This test helps doctors see how well the heart and lungs are working together. The study will also look at other health indicators, such as heart function and exercise capacity, to understand the overall impact of the treatment. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The purpose of the study is to confirm the appropriate doses of selexipag for children aged 2 to 18 years with pulmonary arterial hypertension. The study will observe how the medication is processed in the body and its effects over a period of time. Participants will take the medication orally, and the study will monitor their response to determine if the doses used in children achieve similar effects as those seen in adults.

Throughout the study, children will receive selexipag and will be closely monitored by healthcare professionals to ensure their safety and to assess how well the medication is tolerated. The study aims to gather information on the medication’s safety and how it behaves in the body, which will help in understanding the best way to use selexipag in treating children with this condition.

Participants in the study will receive the medication Riociguat Bayer and may also receive a placebo. The study will involve an open-label approach, meaning that both the participants and the researchers will know which treatment is being administered. The study will include a period of individual dose titration, which means adjusting the dose to find the most effective and safe amount for each participant. The study will last for a maximum of 24 weeks, during which time participants will be monitored for any side effects and changes in their condition.

Throughout the study, various assessments will be conducted, including checking vital signs, performing x-rays, and analyzing blood samples to understand how the medication is working in the body. Participants will also be asked to complete questionnaires about their quality of life and the taste and texture of the pediatric formulation. The study aims to gather important information that could help improve the treatment of pulmonary arterial hypertension in children.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will last for about three months, during which participants will take the tablets by mouth. Throughout the study, various tests will be conducted to assess changes in exercise ability, heart and lung function, and other health indicators. These tests will help researchers understand the impact of dapagliflozin on the body.

The study aims to provide valuable information on whether dapagliflozin can improve the health and quality of life for people with PAH. By comparing the effects of the medication with the placebo, researchers hope to determine its effectiveness and safety in managing this challenging condition. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to gather accurate data on the medication’s effects.